PT - JOURNAL ARTICLE AU - HIROAKI SAITO AU - YUSUKE KONO AU - YUKI MURAKAMI AU - YUJI SHISHIDO AU - HIROHIKO KURODA AU - TOMOYUKI MATSUNAGA AU - YOJI FUKUMOTO AU - TOMOHIRO OSAKI AU - KEIGO ASHIDA AU - YOSHIYUKI FUJIWARA TI - Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression DP - 2018 Jan 01 TA - Anticancer Research PG - 107--112 VI - 38 IP - 1 4099 - http://ar.iiarjournals.org/content/38/1/107.short 4100 - http://ar.iiarjournals.org/content/38/1/107.full SO - Anticancer Res2018 Jan 01; 38 AB - Background: A recent study demonstrated that immune-checkpoint molecules are associated with tumoral immune evasion. Materials and Methods: Programmed cell death protein 1 (PD-1) expression on CD4+ and CD8+ T-cells obtained from gastric cancer tissue was evaluated by multicolor flow cytometry. Immunohistochemical staining was also performed to evaluate programmed cell death ligand-1 (PD-L1) expression on gastric cancer cells. Results: There were statistically significant correlations between PD-L1 expression and age, histology, tumor size, depth of invasion, lymph node metastasis, lymphatic vessel invasion, venous invasion, and disease stage. The 5-year survival rates of patients with and without PD-L1–positive tumors were 48.9% and 80.7%, respectively, and the difference was statistically significant. Multivariate analysis indicated that PD-L1 expression was an independent prognostic indicator. The frequency of PD-1-positive CD4+ and CD8+ T-cells from gastric cancer tissue with PD-L1 expression was significantly more than that from gastric cancer tissue without PD-L1 expression. Conclusion: PD-L1 expression was related to a poor prognosis in patients with gastric cancer. Furthermore, PD-1 expression on T-cells was up-regulated in patients with tumors with PD-L1 expression.